A Causative Role for Amylin in Diabetic Peripheral Neuropathy

Launched by ZABEEN MAHUWALA, MD · Mar 26, 2018

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between a hormone called amylin and a condition known as diabetic peripheral neuropathy, which is a common problem for people with Type 2 diabetes. Peripheral neuropathy can cause symptoms like pain, tingling, and numbness, often in the hands and feet. Researchers want to find out if higher levels of amylin in the upper body are linked to these symptoms. To do this, they will collect blood and skin samples from participants and assess their sensitivity to different temperatures and pressure.

To be eligible for this trial, participants need to have a diagnosis of Type 2 diabetes and show mild to severe signs of peripheral neuropathy, as indicated by specific tests measuring nerve function. The study is open to all adults aged 65 to 74. If you join, you will undergo some tests to help the researchers understand how amylin might be affecting your nerve health. This study could provide important insights into better managing diabetic peripheral neuropathy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject has been diagnosed with Type-2 Diabetes.
• • Subject shows mild-to-severe peripheral neuropathy, as determined by Nerve Conduction Velocity (NCV) tests.
• Exclusion Criteria:
• • Subject has not been diagnosed with Type-2 Diabetes.
• • Subject shows average, or above average performance on Nerve Conduction Velocity (NCV) tests.